EE200000693A - Uudsed makroosakeste formulatsioonid - Google Patents

Uudsed makroosakeste formulatsioonid

Info

Publication number
EE200000693A
EE200000693A EEP200000693A EEP200000693A EE200000693A EE 200000693 A EE200000693 A EE 200000693A EE P200000693 A EEP200000693 A EE P200000693A EE P200000693 A EEP200000693 A EE P200000693A EE 200000693 A EE200000693 A EE 200000693A
Authority
EE
Estonia
Prior art keywords
macroparticle
formulations
novel
novel macroparticle
macroparticle formulations
Prior art date
Application number
EEP200000693A
Other languages
English (en)
Inventor
Perkins Walter
Li Xingong
Hirsch Donald
Mayhew Eric
Ahmad Imran
Ali Shaukat
Janoff Andrew
Original Assignee
The Liposome Company, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Liposome Company, Inc. filed Critical The Liposome Company, Inc.
Publication of EE200000693A publication Critical patent/EE200000693A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000693A 1998-05-20 1999-05-19 Uudsed makroosakeste formulatsioonid EE200000693A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8610898P 1998-05-20 1998-05-20
PCT/US1999/010975 WO1999059550A1 (en) 1998-05-20 1999-05-19 Novel particulate formulations

Publications (1)

Publication Number Publication Date
EE200000693A true EE200000693A (et) 2002-04-15

Family

ID=22196324

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000693A EE200000693A (et) 1998-05-20 1999-05-19 Uudsed makroosakeste formulatsioonid

Country Status (18)

Country Link
US (1) US6500461B2 (et)
EP (1) EP1079812A4 (et)
JP (1) JP2002535242A (et)
KR (1) KR20010052368A (et)
CN (1) CN1310612A (et)
AR (1) AR019308A1 (et)
AU (1) AU745015B2 (et)
BR (1) BR9911031A (et)
CA (1) CA2332545A1 (et)
EA (1) EA200001109A1 (et)
EE (1) EE200000693A (et)
ID (1) ID28166A (et)
IL (1) IL139541A0 (et)
NO (1) NO20005832L (et)
PL (1) PL344327A1 (et)
SK (1) SK17422000A3 (et)
TR (1) TR200003435T2 (et)
WO (1) WO1999059550A1 (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
JP2008506780A (ja) * 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク. 活性剤放出のための粒子状構築物
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
KR20100044225A (ko) 2007-07-21 2010-04-29 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis PARTICULARS FOR IMAGING
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
KR20100098653A (ko) 2007-11-21 2010-09-08 디코드 제네틱스 이에이치에프 염증의 치료를 위한 바이아릴 pde4 억제제
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
EP2344134B1 (en) * 2008-09-23 2017-11-08 The Regents of The University of California Nanocarriers for drug delivery
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2010207486B2 (en) 2009-01-26 2013-03-07 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
CN101670095B (zh) * 2009-04-13 2012-05-23 北京大学 一种用于栓塞治疗的药物组合物及其制备方法
AU2010273732A1 (en) 2009-07-14 2012-02-09 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
JP2013514999A (ja) 2009-12-17 2013-05-02 ワシントン・ユニバーシティ 抗血栓性ナノ粒子
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
WO2018204495A1 (en) 2017-05-02 2018-11-08 Synthetic Genomics, Inc. Nanolipoprotein particles and related compositions methods and systems for loading rna
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
CN113330056A (zh) 2018-08-31 2021-08-31 加利福尼亚大学董事会 基于花青的末端树枝状共聚物及其治疗癌症的用途
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
WO1991019486A1 (en) 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
EP0653935B1 (en) 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
CZ288562B6 (cs) * 1995-09-12 2001-07-11 The Liposome Company, Inc. Taxanové deriváty, farmaceutický prostředek je obsahující a jejich použití
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same

Also Published As

Publication number Publication date
US6500461B2 (en) 2002-12-31
AU745015B2 (en) 2002-03-07
NO20005832D0 (no) 2000-11-17
AU4190699A (en) 1999-12-06
WO1999059550A1 (en) 1999-11-25
CA2332545A1 (en) 1999-11-25
SK17422000A3 (sk) 2001-09-11
EP1079812A4 (en) 2001-12-12
NO20005832L (no) 2001-01-18
BR9911031A (pt) 2002-01-29
US20020034536A1 (en) 2002-03-21
CN1310612A (zh) 2001-08-29
TR200003435T2 (tr) 2001-03-21
IL139541A0 (en) 2004-02-08
AR019308A1 (es) 2002-02-13
EA200001109A1 (ru) 2001-06-25
JP2002535242A (ja) 2002-10-22
PL344327A1 (en) 2001-10-22
EP1079812A1 (en) 2001-03-07
ID28166A (id) 2001-05-10
KR20010052368A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
EE200000693A (et) Uudsed makroosakeste formulatsioonid
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
DK1070058T3 (da) (4-Arylsulfonylamino)-tetrahydropyran-4-carboxylsyrehydroxamider
IS2325B (is) Örgerðar samsetningar epleróns
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
MA24473A1 (fr) Formulations
ID26162A (id) Turunan-turunan benzilbifenil biosida
DE69927758D1 (de) Imidosilan-Zusammensetzungen
DE69928862D1 (de) Zusammensetzung
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
DE69908845D1 (de) Fotoresistzusammensetzung
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
DK0969233T3 (da) Strömningsbegrænser
DE69926606D1 (de) Plazentaprotein 13
PT1076660E (pt) (4-bromopirazol-3-il)-benzazolos substituidos
EP1095060A4 (en) GALEKTIN 11
SE9803106D0 (sv) Novel formulation
FI980629A0 (fi) Brandlucka (foer maskinfalsat plaottak)